BlueSphere Bio To Partner with NMDP BioTherapies℠ for the Company’s First-In-Human TCR-based Product Candidate in Combination with Allogeneic Hematopoietic Cell Transplantation Trial
PITTSBURGH, June 25, 2024 (GLOBE NEWSWIRE) — BlueSphere Bio, a drug development company focused on novel T-cell receptor (TCR) based therapies for oncology and non-oncology indications, today announced a collaboration with NMDP BioTherapies℠ (formerly Be The Match BioTherapies), an organization offering solutions for companies developing and commercializing cell and gene therapies, to advance BlueSphere’s first clinical trial evaluating […]